NEW Zealand's Medicines and Medical Devices Safety Authority, Medsafe, has recommended new lower dosing of Pradaxa (dabigatran) in certain cases, in its latest Prescriber Update.
The new recommendations relate to the treatment/prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Other updates highlight the increased risk of cardiovascular adverse events associated with the use of non-steroidal anti-inflammatory agents and rebound acid hypersecretion following proton pump inhibitor use and many more hot topics.
Visit medsafe.govt.nz to access.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Jun 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Jun 19
